Movatterモバイル変換


[0]ホーム

URL:


FR2413974A1 - DRYER FOR SCREEN-PRINTED SHEETS - Google Patents

DRYER FOR SCREEN-PRINTED SHEETS

Info

Publication number
FR2413974A1
FR2413974A1FR7800305AFR7800305AFR2413974A1FR 2413974 A1FR2413974 A1FR 2413974A1FR 7800305 AFR7800305 AFR 7800305AFR 7800305 AFR7800305 AFR 7800305AFR 2413974 A1FR2413974 A1FR 2413974A1
Authority
FR
France
Prior art keywords
dryer
racks
screen
printed sheets
sheet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7800305A
Other languages
French (fr)
Other versions
FR2413974B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=9203176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2413974(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by IndividualfiledCriticalIndividual
Priority to FR7800305ApriorityCriticalpatent/FR2413974A1/en
Priority to DE7878400265Tprioritypatent/DE2860970D1/en
Priority to EP19780400265prioritypatent/EP0003089B1/en
Publication of FR2413974A1publicationCriticalpatent/FR2413974A1/en
Application grantedgrantedCritical
Publication of FR2413974B1publicationCriticalpatent/FR2413974B1/fr
Grantedlegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

Translated fromFrench

SECHOIR POUR FEUILLES IMPRIMEES PAR SERIGRAPHIE, COMPORTANT UN CONVOYEUR SANS FIN PORTE PAR UN CHASSIS ET AUQUEL SONT FIXEES DES CLAIES ADAPTEES POUR RECEVOIR LES FEUILLES, ET UN DISPOSITIF DE SOUFFLAGE D'AIR SUR CELLES-CI POUR LES SECHER. CE SECHOIR COMPREND UN SYSTEME DE PINCES D'AMARRAGE 9 DE CHAQUE FEUILLE 11 SUR SA CLAIE 7 DE SUPPORT, ASSOCIE A UN DISPOSITIF 22, 18, 17 D'OUVERTURE ET DE FERMETURE AUTOMATIQUES DES PINCES 9 A LA FIN DU CYCLE DE SECHAGE D'UNE FEUILLE 11, AFIN DE PERMETTRE LE RETRAIT DE CELLE-CI DU SECHOIR. LE FAIT D'EQUIPER LES CLAIES DU SECHOIR D'UN SYSTEME D'AMARRAGE DES FEUILLES SUR LEURS CLAIES PERMET D'AUGMENTER LA PUISSANCE DU SOUFFLAGE D'AIR, CE QUI ACCROIT LA RAPIDITE DU SECHAGE. EN OUTRE, CELUI-CI PEUT ETRE EXECUTE AVEC DE L'AIR FROID AU LIEU D'AIR CHAUD PULSE, CE QUI DIMINUE CONSIDERABLEMENT LA QUANTITE D'ENERGIE NECESSAIRE.DRYER FOR SCREEN-PRINTED SHEETS, INCLUDING AN ENDLESS CONVEYOR CARRIED BY A CHASSIS AND TO WHICH ARE FIXED RACKS ADAPTED TO RECEIVE THE SHEETS, AND AN AIR BLOWING DEVICE ON THEM TO DRY THEM. THIS DRYER INCLUDES A SYSTEM OF LOCKING CLAMPS 9 FOR EACH SHEET 11 ON ITS SUPPORT SHELF 7, ASSOCIATED WITH A DEVICE 22, 18, 17 FOR AUTOMATIC OPENING AND CLOSING OF THE CLAMPS 9 AT THE END OF THE DRYING CYCLE. A SHEET 11, IN ORDER TO ALLOW THE REMOVAL OF IT FROM THE DRYER. EQUIPPING THE DRYER RACKS WITH A SYSTEM FOR MOUNTING THE LEAVES ON THEIR RACKS ALLOWS THE POWER OF THE AIR BLOWING TO BE INCREASED, WHICH INCREASES THE SPEED OF THE DRYING. IN ADDITION, THIS CAN BE CARRIED OUT WITH COLD AIR INSTEAD OF HOT PULSE AIR, WHICH CONSIDERALLY REDUCES THE AMOUNT OF ENERGY REQUIRED.

FR7800305A1978-01-061978-01-06 DRYER FOR SCREEN-PRINTED SHEETSGrantedFR2413974A1 (en)

Priority Applications (3)

Application NumberPriority DateFiling DateTitle
FR7800305AFR2413974A1 (en)1978-01-061978-01-06 DRYER FOR SCREEN-PRINTED SHEETS
DE7878400265TDE2860970D1 (en)1978-01-061978-12-27Drier for silkscreen printed sheets
EP19780400265EP0003089B1 (en)1978-01-061978-12-27Drier for silkscreen printed sheets

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
FR7800305AFR2413974A1 (en)1978-01-061978-01-06 DRYER FOR SCREEN-PRINTED SHEETS

Publications (2)

Publication NumberPublication Date
FR2413974A1true FR2413974A1 (en)1979-08-03
FR2413974B1 FR2413974B1 (en)1982-12-03

Family

ID=9203176

Family Applications (1)

Application NumberTitlePriority DateFiling Date
FR7800305AGrantedFR2413974A1 (en)1978-01-061978-01-06 DRYER FOR SCREEN-PRINTED SHEETS

Country Status (3)

CountryLink
EP (1)EP0003089B1 (en)
DE (1)DE2860970D1 (en)
FR (1)FR2413974A1 (en)

Families Citing this family (444)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5708142A (en)1994-05-271998-01-13Genentech, Inc.Tumor necrosis factor receptor-associated factors
US6998116B1 (en)1996-01-092006-02-14Genentech, Inc.Apo-2 ligand
US20050089958A1 (en)*1996-01-092005-04-28Genentech, Inc.Apo-2 ligand
US6030945A (en)*1996-01-092000-02-29Genentech, Inc.Apo-2 ligand
CA2249206A1 (en)1996-04-011997-10-09Genentech, Inc.Apo-2li and apo-3 apoptosis polypeptides
US6159462A (en)*1996-08-162000-12-12Genentech, Inc.Uses of Wnt polypeptides
US5851984A (en)*1996-08-161998-12-22Genentech, Inc.Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6462176B1 (en)1996-09-232002-10-08Genentech, Inc.Apo-3 polypeptide
US5990281A (en)1996-09-301999-11-23Genentech, Inc.Vertebrate smoothened proteins
US6136958A (en)1996-09-302000-10-24Genentech, Inc.Antibodies to vertebrate smoothened proteins
AU729158B2 (en)1997-01-312001-01-25Genentech Inc.O-fucosyltransferase
WO2000039297A2 (en)1998-12-232000-07-06Genentech, Inc.Il-1 related polypeptides
CA2289665C (en)*1997-06-132005-08-09Genentech, Inc.Protein recovery by chromatography followed by filtration upon a charged layer
ES2306480T3 (en)1997-09-182008-11-01Genentech, Inc. DCR3 POLYPEPTIDE, A TNFR HOMOLOGIST.
AU749948B2 (en)1997-10-102002-07-04Genentech Inc.APO-3 ligand
ATE409225T1 (en)1997-10-292008-10-15Genentech Inc GENES INDUCIBLE BY WNT-1
US7192589B2 (en)1998-09-162007-03-20Genentech, Inc.Treatment of inflammatory disorders with STIgMA immunoadhesins
DE69837897T2 (en)1997-11-212008-03-06Genentech Inc., San Francisco A33 related antigens and their pharmaceutical uses
JP2002505850A (en)1997-12-032002-02-26ジェネンテック・インコーポレーテッド Polypeptides and nucleic acids encoding the same
EP1947119A3 (en)1997-12-122012-12-19Genentech, Inc.Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
US6740739B1 (en)1998-01-152004-05-25Genentech, Inc.Substitutional variants of APO-2 ligand
IL138930A0 (en)1998-05-152001-11-25Genentech IncIl-17 homologies polypeptides and therapeutic uses thereof
SI1135498T1 (en)1998-11-182008-06-30Genentech IncAntibody variants with higher binding affinity compared to parent antibodies
EP1820859B9 (en)1998-12-222009-10-28Genentech, Inc.Methods and compositions for inhibiting neoplastic cell growth
HUP0104865A3 (en)1999-01-152004-07-28Genentech IncPolypeptide variants with altered effector function
DE60043322D1 (en)1999-06-152009-12-24Genentech Inc Secreted and transmembrane polypeptides and nucleic acids for their coding
BRPI0012198B8 (en)1999-06-252021-05-25Genentech Inc humanized antibodies, composition and immunoconjugate
DE60042693D1 (en)1999-08-272009-09-17Genentech Inc DOSAGE FOR TREATMENT WITH ANTI ERBB2 ANTIBODIES
EP1669371A3 (en)1999-12-012006-06-21Genentech, Inc.Composition and methods for the diagnosis of tumours
EP2290081A3 (en)1999-12-232012-08-01Genentech, Inc.IL-17 homologous polypeptide and therapeutic uses thereof
AU785055B2 (en)2000-01-132006-09-07Genentech Inc.Novel stra6 polypeptides
US6740520B2 (en)2000-03-212004-05-25Genentech, Inc.Cytokine receptor and nucleic acids encoding the same
WO2004043361A2 (en)2002-11-082004-05-27Genentech, Inc.Compositions and methods for the treatment of natural killer cell related diseases
DK2042597T3 (en)2000-06-232014-08-11Genentech Inc COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF DISEASES INVOLVING ANGIOGENESIS
CA2709771A1 (en)2000-06-232002-01-03Genentech, Inc.Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002009755A2 (en)2000-07-272002-02-07Genentech, Inc.Apo-2l receptor agonist and cpt-11 synergism
US6902734B2 (en)2000-08-072005-06-07Centocor, Inc.Anti-IL-12 antibodies and compositions thereof
UA81743C2 (en)2000-08-072008-02-11Центокор, Инк.HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
ATE412009T1 (en)2000-08-242008-11-15Genentech Inc METHOD FOR INHIBITING IL-22 INDUCED PAP1
EP1944317A3 (en)2000-09-012008-09-17Genentech, Inc.Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE442862T2 (en)2000-10-122009-10-15Genentech Inc LOW VISCOSE CONCENTRATED PROTEIN FORMULATIONS
US20020159996A1 (en)2001-01-312002-10-31Kandasamy HariharanUse of CD23 antagonists for the treatment of neoplastic disorders
US7087726B2 (en)2001-02-222006-08-08Genentech, Inc.Anti-interferon-α antibodies
CN101653604A (en)2001-05-302010-02-24基因技术股份有限公司Anti-ngf antibodies for the treatment of various disorders
US20070160576A1 (en)2001-06-052007-07-12Genentech, Inc.IL-17A/F heterologous polypeptides and therapeutic uses thereof
AU2002318371B2 (en)2001-06-202006-06-15Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumor
BR0212070A (en)2001-08-292004-09-28Genentech Inc bv8 nucleic acids and polypeptides with mitogenic activity
DE60238143D1 (en)2001-09-182010-12-09Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF TUMORS
WO2004039826A1 (en)2001-11-142004-05-13Centocor, Inc.Anti-il-6 antibodies, compositions, methods and uses
JP4063769B2 (en)2001-12-282008-03-19中外製薬株式会社 Protein stabilization method
US20030228305A1 (en)2002-01-022003-12-11Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumor
US7452675B2 (en)2002-01-252008-11-18The Queen's Medical CenterMethods of screening for TRPM4b modulators
JP2005535290A (en)2002-02-222005-11-24ジェネンテック・インコーポレーテッド Compositions and methods for the treatment of immune related diseases
DK1485477T3 (en)2002-02-252009-08-10Genentech Inc New type 1 cytokine receptor GLM-R
EP2305710A3 (en)2002-06-032013-05-29Genentech, Inc.Synthetic antibody phage libraries
BR0312534A (en)2002-07-152007-03-13Genentech Inc Tumor identification method, Tumor cell identification method, Method for predicting the response of an individual diagnosed with a her2-positive tumor, Method for identification of an individual responsive to anti-her2 antibody treatment and Methods of treatment of a patient and article of manufacture
EP2116551A1 (en)2002-09-112009-11-11Genentech, Inc.Compositions and methods for the treatment of immune related diseases
EP2332996B1 (en)2002-09-112014-10-15Genentech, Inc.Purification of anti-Her2 antibodies
WO2004024097A2 (en)2002-09-162004-03-25Genentech, Inc.Compositions and methods for the treatment of immune related diseases
AU2003279084A1 (en)2002-09-252004-04-19Genentech, Inc.Novel compositions and methods for the treatment of psoriasis
EP2322200A3 (en)2002-10-292011-07-27Genentech, Inc.Compositions and methods for the treatment of immune related diseases
AU2003302386B2 (en)2002-11-262010-04-01Genentech, Inc.Compositions and methods for the treatment of immune related diseases
US7569364B2 (en)2002-12-242009-08-04Pfizer Inc.Anti-NGF antibodies and methods using same
KR101410692B1 (en)2002-12-242014-06-24리나트 뉴로사이언스 코프.Anti-ngf antibodies and methods using same
CA2515288A1 (en)2003-03-122004-09-23Genentech, Inc.Compositions with hematopoietic and immune activity
AU2003237792A1 (en)2003-04-012004-11-23Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumor
RS20150135A1 (en)2003-05-302015-08-31Genentech Inc.Treatment with anti-vegf antibodies
US9708410B2 (en)2003-05-302017-07-18Janssen Biotech, Inc.Anti-tissue factor antibodies and compositions
CA2526402A1 (en)2003-06-052005-01-20Genentech, Inc.Blys antagonists and uses thereof
EP1635692B1 (en)2003-06-132010-04-21University of PittsburghMonitoring immunologic, hematologic and inflammatory diseases
DK2784084T4 (en)2003-07-082024-01-08Novartis Pharma Ag Antagonist antibodies against IL-17A/F heterologous polypeptides
SI3095793T1 (en)2003-07-282020-07-31Genentech, Inc.Reducing protein a leaching during protein a affinity chromatography
WO2005014818A1 (en)2003-08-082005-02-17Perseus Proteomics Inc.Gene overexpressed in cancer
WO2005019258A2 (en)2003-08-112005-03-03Genentech, Inc.Compositions and methods for the treatment of immune related diseases
PL2161283T3 (en)2003-11-172014-11-28Genentech IncCompositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin
WO2005060520A2 (en)2003-11-252005-07-07Dana-Farber Cancer Institute, Inc.ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
US7312320B2 (en)2003-12-102007-12-25Novimmune SaNeutralizing antibodies and methods of use thereof
WO2005058965A1 (en)2003-12-112005-06-30Genentech, Inc.Methods and compositions for inhibiting c-met dimerization and activation
EP2402756A3 (en)2003-12-232012-02-22Rinat Neuroscience Corp.Agonist anti-trkC antibodies and methods using same
EP1716181B1 (en)2004-02-192009-12-16Genentech, Inc.Cdr-repaired antibodies
TW201422238A (en)2004-06-042014-06-16Genentech IncUse of CD20 antibody in treatment of multiple sclerosis and an article for the use
NZ552956A (en)2004-07-202010-03-26Genentech IncInhibitors of angiopoietin-like 4 protein (ANGPTL4), combinations, and their use for treating cancer
SG190665A1 (en)2004-07-302013-06-28Rinat Neuroscience CorpAntibodies directed against amyloid-beta peptide and methods using same
JO3000B1 (en)2004-10-202016-09-05Genentech IncAntibody Formulations.
ATE462726T1 (en)2005-01-072010-04-15Diadexus Inc OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
KR20150083139A (en)2005-01-212015-07-16제넨테크, 인크.Fixed dosing of her antibodies
US8029783B2 (en)2005-02-022011-10-04Genentech, Inc.DR5 antibodies and articles of manufacture containing same
CA2597924C (en)2005-02-152018-10-02Duke UniversityAnti-cd19 antibodies and uses in oncology
DK1850874T3 (en)2005-02-232013-11-11Genentech Inc Extension of time to disease progression or survival for ovarian cancer using pertuzumab
ATE526412T1 (en)2005-04-112011-10-15Ca Nat Research Council IDENTIFICATION OF A BETA-1,3-N-ACETYL GALACTOSAMINYL TRANSFERASE (CGTE) FROM CAMPYLOBACTER JEJUNI LIO87
EP2267450B1 (en)2005-04-292015-01-28The Regents of The University of CaliforniaAntibodies against histone modifications for clinical diagnosis and prognosis of cancer
JO3058B1 (en)2005-04-292017-03-15Applied Molecular Evolution IncAnti-IL-6 Antibodies,Compositions,Methods and uses
JP5047947B2 (en)2005-05-052012-10-10デューク ユニバーシティ Anti-CD19 antibody treatment for autoimmune disease
EP1899364B2 (en)2005-05-172024-10-30University of ConnecticutCompositions and methods for immunomodulation in an organism
TR201902033T4 (en)2005-06-302019-03-21Janssen Biotech Inc Anti-IL-23 antibodies, compositions, methods and uses.
US8217147B2 (en)2005-08-102012-07-10Macrogenics, Inc.Identification and engineering of antibodies with variant Fc regions and methods of using same
RS20080200A (en)2005-11-142009-07-15Rinat Neuroscience Corp.,Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP3006466B1 (en)2005-12-022018-08-01Genentech, Inc.Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
CA2632094C (en)2005-12-022015-01-27Wayne A. MarascoCarbonic anhydrase ix (g250) antibodies and methods of use thereof
RU2008128134A (en)2005-12-152010-01-20Дженентек, Инк. (Us) METHODS AND COMPOSITIONS FOR OBJECTIVING POLYUBIKVITIN
HUE049832T2 (en)2005-12-292020-10-28Janssen Biotech IncHuman anti-il-23 antibodies, compositions, method and uses
KR101589391B1 (en)2006-01-052016-01-29제넨테크, 인크.Anti-ephb4 antibodies and methods using same
EP1982181B1 (en)2006-02-062010-12-15Rhode Island HospitalGpr30 estrogen receptor in breast cancers
JP2009527227A (en)2006-02-172009-07-30ジェネンテック・インコーポレーテッド Gene disruption and related compositions and methods
EP2650306A1 (en)2006-03-062013-10-16Aeres Biomedical LimitedHumanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US20100278821A1 (en)2006-03-212010-11-04The Regents Of The University Of CaliforniaN-cadherin: target for cancer diagnosis and therapy
JP5298007B2 (en)2006-03-212013-09-25ジェネンテック, インコーポレイテッド Combinatorial therapy with alpha5beta1 antagonist
EP2390666A1 (en)2006-03-212011-11-30The Regents of The University of CaliforniaN-Cadherin as target for cancer diagnosis and therapy
CA2647107A1 (en)2006-03-232007-09-27Novartis AgAnti-tumor cell antigen antibody therapeutics
CA2647277A1 (en)2006-04-052007-11-08Genentech, Inc.Method for using boc/cdo to modulate hedgehog signaling
JP2009536526A (en)2006-05-042009-10-15ジェネンテック・インコーポレーテッド Methods and compositions related to ZPA polypeptides
SG172656A1 (en)2006-05-302011-07-28Genentech IncAntibodies and immunoconjugates and uses therefor
EP2024391A2 (en)2006-06-012009-02-18Genentech, Inc.Crystal structure of crig and c3b: crig complex
US7674605B2 (en)2006-06-072010-03-09Bioalliance C.V.Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US7572618B2 (en)2006-06-302009-08-11Bristol-Myers Squibb CompanyPolynucleotides encoding novel PCSK9 variants
EP2471815B1 (en)2006-07-112016-03-30University Of Medicine And Dentistry Of New JerseyProteins, nucleic acids encoding the same and associated methods of use
JP2009543579A (en)2006-07-192009-12-10ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア WSX-1 / p28 as a target for anti-inflammatory response
EP2520935A3 (en)2006-08-092013-02-13Homestead Clinical CorporationOrgan-specific proteins and methods of their use
CN101506237B (en)2006-08-222014-05-07G2炎症私人有限公司 Anti-C5aR antibodies with improved properties
JP2010501172A (en)2006-08-252010-01-21オンコセラピー・サイエンス株式会社 Prognostic markers and therapeutic targets for lung cancer
CN101557818A (en)2006-10-032009-10-14新泽西医科和牙科大学ATAP peptides, nucleic acids encoding the same, and related methods of use
DK2502938T3 (en)2006-10-272015-04-20Genentech IncAntibodies and immunoconjugates and uses thereof
WO2008140586A2 (en)2006-11-212008-11-20The Regents Of The University Of CaliforniaModulation of rhamm (cd168) for selective adipose tissue development
CA2670696A1 (en)2006-11-272008-06-05Diadexus, Inc.Ovr110 antibody compositions and methods of use
ATE541059T1 (en)2007-02-222012-01-15Genentech Inc METHOD FOR DETECTING INFLAMMABLE BOWEL DISEASE
NZ578824A (en)2007-03-022012-03-30Genentech IncPredicting response to a her dimerisation inhibitor based on low her3 expression
EP2703011A3 (en)2007-05-072014-03-26MedImmune, LLCAnti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2689680C (en)2007-05-142017-11-07Novimmune SaFc receptor-binding polypeptides with modified effector functions
SI2171090T1 (en)2007-06-082013-07-31Genentech, Inc.Gene expression markers of tumor resistance to her2 inhibitor treatment
EP2980100A1 (en)2007-06-082016-02-03Australian Poultry CRC Pty LtdClostridial toxin netb
SI2188302T1 (en)2007-07-092018-07-31Genentech, Inc.Prevention of disulfide bond reduction during recombinant production of polypeptides
RU2557319C2 (en)2007-07-162015-07-20Дженентек, Инк.HUMANISED ANTIBODIES AGAINST CD79b AND IMMUNOCONJUGATES AND METHODS OF APPLICATION
DK2176296T3 (en)2007-07-162012-05-21Genentech Inc Anti-CD79B antibodies and immune conjugates and methods of use.
DK2185719T3 (en)2007-08-022014-02-17Novimmune Sa ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF
WO2009046123A2 (en)2007-10-022009-04-09Genentech, Inc.Nlrr-1 antagonists and uses thereof
LT2514436T (en)2007-11-072018-04-10Genentech, Inc.Il-22 for use in treating microbial disorders
CA2706729A1 (en)2007-11-292009-06-11Genentech, Inc.Gene expression markers for inflammatory bowel disease
TWI580694B (en)2007-11-302017-05-01建南德克公司Anti-vegf antibodies
US8883146B2 (en)2007-11-302014-11-11Abbvie Inc.Protein formulations and methods of making same
CA2707483A1 (en)2007-11-302009-06-11Wolfgang FraunhoferProtein formulations and methods of making same
WO2009079259A2 (en)2007-12-062009-06-25Dana-Farber Cancer Institute, Inc.Antibodies against influenza virus and methods of use thereof
KR20130087632A (en)2007-12-172013-08-06화이자 리미티드Treatment of interstitial cystitis
CN101918448A (en)2007-12-182010-12-15生物联合公司Antibodies that recognize carbohydrate-containing epitopes of CD-43 and CEA expressed on cancer cells and methods of use thereof
EP4470556A3 (en)2008-01-152025-04-23The Board of Trustees of the Leland Stanford Junior UniversityMarkers of acute myeloid leukemia stem cells
TWI472339B (en)2008-01-302015-02-11Genentech IncComposition comprising antibody that binds to domain ii of her2 and acidic variants thereof
MX351557B (en)2008-01-312017-10-19Genentech IncANTI-CD79B ANTIBODIES and IMMUNOCONJUGATES and METHODS OF USE.
CN110082533B (en)2008-04-092023-01-10健泰科生物技术公司 Novel compositions and methods for the treatment of immune-related diseases
US20100255508A1 (en)2008-05-162010-10-07Thomas Richard GelzleichterUse of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
US9226934B2 (en)2008-06-022016-01-05The University Of TokyoAnti-cancer drug
US8999702B2 (en)2008-06-112015-04-07Emd Millipore CorporationStirred tank bioreactor
WO2009150623A1 (en)2008-06-132009-12-17Pfizer IncTreatment of chronic prostatitis
EP3301116A1 (en)2008-08-252018-04-04Dana Farber Cancer Institute, Inc.Conserved influenza hemagglutinin epitope and antibodies thereto
US8790642B2 (en)2008-08-292014-07-29Genentech, Inc.Cross-reactive and bispecific anti-IL-17A/F antibodies
JP5859307B2 (en)2008-09-102016-02-10ジェネンテック, インコーポレイテッド Methods for inhibiting ocular neovascularization
TWI516501B (en)2008-09-122016-01-11禮納特神經系統科學公司Pcsk9 antagonists
TW201438738A (en)2008-09-162014-10-16Genentech Inc Method for treating progressive multiple sclerosis
RU2581962C2 (en)2008-09-192016-04-20Медиммун ЛлкTargeted binding agents against dll4 and application thereof
ES2828721T3 (en)2008-10-142021-05-27Genentech Inc Immunoglobulin variants and their uses
WO2010056804A1 (en)2008-11-122010-05-20Medimmune, LlcAntibody formulation
US20110020327A1 (en)2008-12-162011-01-27Millipore CorporationPurification of proteins
AU2009335788A1 (en)2008-12-172011-07-07Genentech, Inc.Hepatitis C virus combination therapy
WO2010075249A2 (en)2008-12-222010-07-01Genentech, Inc.A method for treating rheumatoid arthritis with b-cell antagonists
JP2012513194A (en)2008-12-232012-06-14アストラゼネカ アクチボラグ Targeted binding agents directed to α5β1 and uses thereof
US20120009182A1 (en)2008-12-232012-01-12Genentech, Inc.Immunoglobulin variants with altered binding to protein a
WO2010086828A2 (en)2009-02-022010-08-05Rinat Neuroscience CorporationAgonist anti-trkb monoclonal antibodies
SI3260136T1 (en)2009-03-172021-05-31Theraclone Sciences, Inc.Human immunodeficiency virus (hiv) -neutralizing antibodies
HRP20150965T1 (en)2009-03-252015-11-06Genentech, Inc. ANTI-FGR3 ANTIBODIES AND METHODS USED
JP6132548B2 (en)2009-04-012017-05-24ジェネンテック, インコーポレイテッド Anti-FcRH5 antibodies and immunoconjugates and methods of use
KR101811886B1 (en)2009-05-052017-12-22노비뮨 에스 에이Anti-IL-17F Antibodies and Methods of Use Thereof
WO2010146511A1 (en)2009-06-172010-12-23Pfizer LimitedTreatment of overactive bladder
EP2451843A1 (en)2009-07-072012-05-16F. Hoffmann-La Roche AGDiagnosis and treatment of autoimmune demyelinating diseases
US20110033486A1 (en)2009-07-202011-02-10Abbas Alexander RGene expression markers for crohn's disease
TW201106972A (en)2009-07-272011-03-01Genentech IncCombination treatments
EP4559926A3 (en)2009-08-062025-08-06F. Hoffmann-La Roche AGVirus filtration methods
US20110039300A1 (en)2009-08-102011-02-17Robert BayerAntibodies with enhanced adcc functions
WO2011019679A1 (en)2009-08-112011-02-17Allergan, Inc.Ccr2 inhibitors for treating conditions of the eye
FI2464725T4 (en)2009-08-112025-03-21Hoffmann La RocheProduction of proteins in glutamine-free cell culture media
US20110053223A1 (en)2009-08-142011-03-03Robert BayerCell culture methods to make antibodies with enhanced adcc function
PL2473617T3 (en)2009-09-012020-06-29F. Hoffmann-La Roche AgEnhanced protein purification through a modified protein a elution
ES2599076T3 (en)2009-09-022017-01-31Genentech, Inc. Smoothened mutant and methods of use thereof
DK2486141T3 (en)2009-10-072018-04-23Macrogenics Inc FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE
WO2011046515A1 (en)2009-10-142011-04-21Nanyang Technological UniversityAntiproliferative agent
JP5814925B2 (en)2009-10-222015-11-17ジェネンテック, インコーポレイテッド Anti-hepsin antibody and method of use thereof
US8697386B2 (en)2009-10-222014-04-15Genentech, Inc.Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056497A1 (en)2009-10-262011-05-12Genentech, Inc.Activin receptor type iib compositions and methods of use
WO2011056502A1 (en)2009-10-262011-05-12Genentech, Inc.Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en)2009-10-262011-05-12Genentech, Inc.Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
ES2636971T3 (en)2009-11-052017-10-10F. Hoffmann-La Roche Ag Procedures and composition for secretion of heterogeneous polypeptides
KR20120103587A (en)2009-11-122012-09-19제넨테크, 인크.A method of promoting dendritic spine density
EP2501409A4 (en)2009-11-202015-02-18Univ California EPITHELIAL MEMBRANE PROTEIN 2 (EMP2) AND PROLIFERATIVE VITREORETINOPATHY (PVR)
ES2646863T3 (en)2009-11-242017-12-18Medimmune Limited B7-H1 specific binding agents
CA2781887C (en)2009-11-302018-03-27Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumor
AR078377A1 (en)2009-12-112011-11-02Genentech Inc ANTI-VEGF-C ANTIBODIES (ISOLATED ANTI-VASCULAR ENDOTELIAL GROWTH FACTOR C) AND ITS METHODS OF USE
RU2609658C2 (en)2009-12-212017-02-02Дженентек, Инк.Composition containing antibody
KR20120107503A (en)2009-12-232012-10-02제넨테크, 인크.Anti-bv8 antibodies and uses thereof
ES2701626T3 (en)2009-12-282019-02-25Oncotherapy Science Inc Anti-CDH3 antibodies and their uses
WO2011082187A1 (en)2009-12-302011-07-07Genentech, Inc.Methods for modulating a pdgf-aa mediated biological response
US20130137584A1 (en)2010-02-012013-05-30The Regents Of The University Of CaliforniaNovel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
WO2011100403A1 (en)2010-02-102011-08-18Immunogen, IncCd20 antibodies and uses thereof
EP4219560A3 (en)2010-02-182023-08-23The Regents of The University of CaliforniaIntegrin alpha v beta 8 neutralizing antibody
CN102985113B (en)2010-02-232015-05-20霍夫曼-拉罗奇有限公司Compositions and methods for the diagnosis and treatment of tumor
TWI552760B (en)2010-02-242016-10-11雷那特神經科學股份有限公司Antagonist anti-il-7 receptor antibodies and methods
PE20130393A1 (en)2010-03-112013-04-07Rinat Neuroscience Corp ANTIBODIES WITH PH-DEPENDENT ANTIGEN UNION
PT2552961T (en)2010-03-302018-03-01Janssen Biotech IncHumanized il-25 antibodies
CN107090045A (en)2010-05-032017-08-25霍夫曼-拉罗奇有限公司Composition and method for tumor diagnosis and therapy
CN102958538A (en)2010-05-032013-03-06弗·哈夫曼-拉罗切有限公司Compositions and methods useful for reducing the viscosity of protein-containing formulations
US8691918B2 (en)2010-05-172014-04-08Emd Millipore CorporationStimulus responsive polymers for the purification of biomolecules
WO2011146568A1 (en)2010-05-192011-11-24Genentech, Inc.Predicting response to a her inhibitor
CA2799915C (en)2010-05-252023-09-26Genentech, Inc.Methods of purifying polypeptides
KR20190067277A (en)2010-05-282019-06-14제넨테크, 인크.Decreasing lactate level and increasing polypeptide production by downregulating ldh and pdhk expression
EP3957653A1 (en)2010-06-022022-02-23Dana Farber Cancer Institute, Inc.Humanized monoclonal antibodies and methods of use
RU2613886C2 (en)2010-06-032017-03-21Дженентек, Инк.Antibodies and immunoconjugates rendered by immuno-positron emission tomography, methods of application
US20110311527A1 (en)2010-06-162011-12-22Allergan, Inc.IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
KR101834026B1 (en)2010-06-192018-03-02메모리얼 슬로안-케터링 캔서 센터Anti-gd2 antibodies
WO2012019061A2 (en)2010-08-052012-02-09Stem Centrx, Inc.Novel effectors and methods of use
MX2013001267A (en)2010-08-132013-04-10Genentech IncAntibodies to il-1beta and il-18, for treatment of disease.
PH12013500379A1 (en)2010-08-272013-03-25Abbvie Stemcentrx LlcNotum protein modulators and methods of use
ES2920140T3 (en)2010-08-312022-08-01Theraclone Sciences Inc Human immunodeficiency virus (HIV) neutralizing antibodies
WO2012030512A1 (en)2010-09-032012-03-08Percivia Llc.Flow-through protein purification process
CN106620693A (en)2010-09-032017-05-10艾伯维施特姆森特克斯有限责任公司Novel modulators and methods of use
AU2011312205B2 (en)2010-10-052015-08-13Curis, Inc.Mutant smoothened and methods of using the same
KR101973930B1 (en)2010-11-052019-04-29자임워크스 인코포레이티드Stable heterodimeric antibody design with mutations in the fc domain
EP2640831A1 (en)2010-11-172013-09-25Sea Lane Biotechnologies,llc.Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
WO2012071436A1 (en)2010-11-242012-05-31Genentech, Inc.Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
RU2016123839A (en)2010-12-082018-11-30АббВай Стемсентркс ЭлЭлСи New modulators and methods of their application
WO2012092539A2 (en)2010-12-312012-07-05Takeda Pharmaceutical Company LimitedAntibodies to dll4 and uses thereof
SA112330278B1 (en)2011-02-182015-10-09ستيم سينتركس، انك.Novel modulators and methods of use
WO2012125614A1 (en)2011-03-152012-09-20Theraclone Sciences, Inc.Compositions and methods for the therapy and diagnosis of influenza
KR102148063B1 (en)2011-03-312020-08-25제넨테크, 인크.Methods of administering beta7 integrin antagonists
SG194111A1 (en)2011-04-072013-11-29Amgen IncNovel egfr binding proteins
ES2704038T3 (en)2011-05-242019-03-13Zyngenia Inc Multivalent and monovalent multispecific complexes and their uses
EP2734546A1 (en)2011-07-182014-05-28Amgen Inc.Apelin antigen-binding proteins and uses thereof
ES2717536T5 (en)2011-11-022025-02-04Hoffmann La RocheOverload and elute chromatography
KR102052774B1 (en)2011-11-042019-12-04자임워크스 인코포레이티드Stable heterodimeric antibody design with mutations in the fc domain
SA112330988B1 (en)2011-11-112015-07-22رينات نيوروساينس كورب. TROP-2 Antibodies and Their Uses
WO2013093693A1 (en)2011-12-222013-06-27Rinat Neuroscience Corp.Staphylococcus aureus specific antibodies and uses thereof
SG11201402828XA (en)2011-12-222014-10-30Rinat Neuroscience CorpHuman growth hormone receptor antagonist antibodies and methods of use thereof
EP2793941A1 (en)2011-12-232014-10-29F.Hoffmann-La Roche AgArticles of manufacture and methods for co-administration of antibodies
WO2013101771A2 (en)2011-12-302013-07-04Genentech, Inc.Compositions and method for treating autoimmune diseases
CN104411717A (en)2012-01-092015-03-11斯克利普斯研究所Humanized antibodies with ultralong CDR3S
JP6684490B2 (en)2012-01-092020-04-22ザ・スクリップス・リサーチ・インスティテュート Ultralong complementarity determining regions and uses thereof
US9045541B2 (en)2012-02-062015-06-02Inhibrx LlcCD47 antibodies and methods of use thereof
JP6089047B2 (en)2012-02-242017-03-01アッヴィ・ステムセントルクス・エル・エル・シー DLL3 modulator and method of use
CN104540851B (en)2012-03-292017-09-15诺夫免疫股份有限公司 Anti-TLR4 antibodies and uses thereof
CA2871751C (en)2012-05-042021-08-24Dana-Farber Cancer Institute, Inc.Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
US20130336973A1 (en)2012-05-102013-12-19Zymeworks Inc.Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain
BR112014031028A2 (en)2012-06-112017-08-15Amgen Inc ANTIGEN-BINDING PROTEIN ISOLATED, NUCLLEIC ACID ISOLATED, EXPRESSION VECTOR, HOST CELL, METHOD FOR PRODUCING AN ANTIGEN-BINDING PROTEIN, COMPOSITION, METHOD FOR REDUCING OR BLOCKING THE ACTIVITY OF MYOSTATIN, ACTIVIN A OR GDF-11, METHOD FOR ENHANCEMENT MUSCLE MASS FIRMNESS OR INCREASE THE MUSCLE MASS FIRMITY TO FAT MASS RATIO IN AN INDIVIDUAL IN NEED OF THE MENTIONED TREATMENT, METHOD FOR TREATMENT OR PREVENTION OF A HARMFUL DISEASE OF MUSCLE IN AN INDIVIDUAL SUFFERING FROM THE SAID DISORDER AND DUAL ANTAGONIST RECEPTOR ANTIBODY
US20150175979A1 (en)2012-07-232015-06-25La Jolla Institute For Allergy And ImmunologyPtprs and proteoglycans in autoimmune disease
EP3401337A1 (en)2012-09-252018-11-14Glenmark Pharmaceuticals S.A.Purification of hetero-dimeric immunoglobulins
CA3139031A1 (en)2012-10-042014-04-10Dana-Farber Cancer Institute, Inc.Human monoclonal anti-pd-l1 antibodies and methods of use
CN104870056A (en)2012-10-052015-08-26弗·哈夫曼-拉罗切有限公司Methods for diagnosing and treating inflammatory bowel disease
EP2917237A1 (en)2012-11-092015-09-16Pfizer Inc.Platelet-derived growth factor b specific antibodies and compositions and uses thereof
RU2019118257A (en)2012-12-032019-06-24Новиммун С.А. ANTI-CD47 ANTIBODIES AND METHODS OF THEIR APPLICATION
JP2016507555A (en)2013-02-062016-03-10インヒブルクス エルピー Non-platelet and non-erythrocyte-reducing CD47 antibodies and methods of use thereof
WO2014130879A2 (en)2013-02-222014-08-28Stem Centrx, Inc.Novel antibody conjugates and uses thereof
RS60534B1 (en)2013-03-132020-08-31Hoffmann La RocheFormulations with reduced oxidation
CA2906057A1 (en)2013-03-132014-10-02Genentech, Inc.Antibody formulations
HRP20181504T1 (en)2013-03-132018-11-02F. Hoffmann - La Roche Ag FORMULATIONS WITH REDUCED OXIDATION
RU2680267C2 (en)2013-03-152019-02-19Мемориал Слоан Кеттеринг Кэнсер СентерHigh-affinity anti-gd2 antibodies
AU2014227909C1 (en)2013-03-152021-11-25Dana-Farber Cancer Institute, Inc.Flavivirus neutralizing antibodies and methods of use thereof
CN105451767B (en)2013-03-152019-10-18泽恩格尼亚股份有限公司Multivalence and monovalent polyspecific compound and application thereof
PL2970875T3 (en)2013-03-152020-08-10F.Hoffmann-La Roche Ag Antioxidant Cell Culture Compositions and Polypeptide Production Methods
US9447193B2 (en)2013-03-242016-09-20Development Center For BiotechnologyMethods for suppressing cancer by inhibition of TMCC3
WO2014160753A1 (en)2013-03-272014-10-02Genentech, Inc.Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
CN105392882A (en)2013-04-192016-03-09加利福尼亚大学董事会Lone star virus
CA2911412A1 (en)2013-05-072014-11-13Rinat Neuroscience Corp.Anti-glucagon receptor antibodies and methods of use thereof
MX368107B (en)2013-07-122019-09-18Genentech IncElucidation of ion exchange chromatography input optimization.
HRP20201404T1 (en)2013-07-162020-11-27F. Hoffmann - La Roche Ag PROCEDURES FOR THE TREATMENT OF CANCER USING PD-1 BASIC BINDING ANTAGONIST AND TIGIT INHIBITOR
CN105814074B (en)2013-07-182020-04-21图鲁斯生物科学有限责任公司 Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en)2013-07-182015-02-05Fabrus, Inc.Antibodies with ultralong complementarity determining regions
KR20160042438A (en)2013-08-122016-04-19제넨테크, 인크.Compositions and method for treating complement-associated conditions
JP6617239B2 (en)2013-08-142019-12-11サイドゥ サチデーブ Antibodies against Frizzled protein and methods of use thereof
JP2016538318A (en)2013-08-282016-12-08ステムセントリックス, インコーポレイテッド New SEZ6 modulator and method of use
CA2922547C (en)2013-08-282020-03-10Stemcentrx, Inc.Site-specific antibody conjugation methods and compositions
AU2014312031A1 (en)2013-08-292016-03-24City Of HopeCell penetrating conjugates and methods of use thereof
JP6942465B2 (en)2013-09-272021-09-29ジェネンテック, インコーポレイテッド Anti-PDL1 antibody preparation
EA036577B1 (en)2013-11-042020-11-25Икнос Сайенсиз СаProduction of t cell retargeting hetero-dimeric immunoglobulins
PE20161092A1 (en)2013-11-132016-10-28Pfizer SPECIFIC ANTIBODIES FOR LIGAND 1A TYPE FACTOR OF TUMOR NECROSIS AND COMPOSITIONS AND USE OF THEM
JP6667437B2 (en)2013-12-022020-03-18ベイラー カレッジ オブ メディスンBaylor College Of Medicine Identification of novel polypeptide hormones for maintaining optimal weight and blood glucose
WO2015087187A1 (en)2013-12-102015-06-18Rinat Neuroscience Corp.Anti-sclerostin antibodies
KR20160099092A (en)2013-12-172016-08-19제넨테크, 인크.Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
RU2016128726A (en)2013-12-172018-01-23Дженентек, Инк. METHODS FOR TREATING MALIGNANT TUMORS USING PD-1 BINDING ANTAGONISTS AND ANTIBODIES AGAINST CD20
AU2014364601A1 (en)2013-12-172016-07-07Genentech, Inc.Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies
SG10201805933TA (en)2013-12-242018-08-30Janssen Pharmaceutica NvAnti-vista antibodies and fragments
EP3094352B1 (en)2014-01-162020-09-23Academia SinicaCompositions and methods for treatment and detection of cancers
WO2016114819A1 (en)2015-01-162016-07-21Academia SinicaCompositions and methods for treatment and detection of cancers
WO2015109212A1 (en)2014-01-172015-07-23Pfizer Inc.Anti-il-2 antibodies and compositions and uses thereof
US20170044232A1 (en)2014-02-042017-02-16Genentech, Inc.Mutant smoothened and methods of using the same
CA2940196C (en)2014-03-192023-03-07Wayne MarascoImmunogenetic restriction on elicitation of antibodies
DK3119431T3 (en)2014-03-212024-03-18Teva Pharmaceuticals Int Gmbh ANTAGONISTS DIRECTED AGAINST CALCITONING-RELATED PEPTIDE AND METHODS OF USING THEREOF
KR20220065091A (en)2014-03-272022-05-19제넨테크, 인크.Methods for diagnosing and treating inflammatory bowel disease
EP3131917B1 (en)2014-04-182020-06-17The Board of Trustees of the Leland Stanford Junior UniversityHumanized and chimeric monoclonal antibodies to cd99
SMT201900745T1 (en)2014-05-302020-01-14Henlix Biotech Co LtdAnti-epidermal growth factor receptor (egfr) antibodies
ES2779412T3 (en)2014-06-172020-08-17Medimmune Ltd Enhanced Alpha-V Beta-8 Antibodies
TWI695011B (en)2014-06-182020-06-01美商梅爾莎納醫療公司Monoclonal antibodies against her2 epitope and methods of use thereof
KR20170062485A (en)2014-10-032017-06-07다나-파버 캔서 인스티튜트 인크.Glucocorticoid-induced tumor necrosis factor receptor(gitr) antibodies and methods of use thereof
JP6795505B2 (en)2014-10-062020-12-02デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Humanized CC chemokine receptor 4 (CCR4) antibody and its usage
RU2705274C2 (en)2014-11-052019-11-06Дженентек, Инк.Methods for producing double-stranded proteins in bacteria
HRP20201351T1 (en)2014-11-052020-11-27Genentech, Inc. PROCEDURES FOR THE PRODUCTION OF TWO - CHAIN PROTEINS IN BACTERIA
CA2967368A1 (en)2014-11-172016-05-26Genentech, Inc.Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
TWI595006B (en)2014-12-092017-08-11禮納特神經系統科學公司 Anti-PD-1 antibodies and methods of using same
US10689423B2 (en)2015-01-132020-06-23City Of HopeCTLA4-binding protein peptide-linker masks
JP7260248B2 (en)2015-01-162023-04-18シティ・オブ・ホープ cell permeable antibody
TWI710571B (en)2015-01-242020-11-21中央研究院Cancer markers and methods of use thereof
HK1244512A1 (en)2015-02-042018-08-10健泰科生物技术公司Mutant smoothened and methods of using the same
CN113209289A (en)2015-02-262021-08-06豪夫迈·罗氏有限公司Integrin beta 7 antagonists and methods for treating Crohn's disease
CN107614523A (en)2015-03-302018-01-19希望之城 mechanical interlocking complex
KR102721595B1 (en)2015-04-032024-10-23유레카 쎄라퓨틱스, 인코포레이티드 Constructs targeting AFP peptide/MHC complexes and uses thereof
CN107750253B (en)2015-04-082022-10-04达纳-法伯癌症研究所公司Humanized influenza monoclonal antibodies and methods of use thereof
TWI703157B (en)2015-04-132020-09-01美商輝瑞股份有限公司Cd3-specific antibodies, therapeutic bispecific antibodies and their uses
NZ736863A (en)2015-05-012024-04-26Dana Farber Cancer Inst IncMethods of mediating cytokine expression with anti ccr4 antibodies
ES2852973T3 (en)2015-05-152021-09-14Hope City Chimeric antigen receptor compositions
ES2962885T3 (en)2015-05-152024-03-21Massachusetts Gen Hospital Tumor necrosis factor receptor superfamily antagonist antibodies
WO2016196381A1 (en)2015-05-292016-12-08Genentech, Inc.Pd-l1 promoter methylation in cancer
CN107810012A (en)2015-06-022018-03-16豪夫迈·罗氏有限公司Use the composition and method of the anti-Antybody therapy sacred diseases of IL 34
CN116327953A (en)2015-06-172023-06-27豪夫迈·罗氏有限公司Methods of treating locally advanced or metastatic breast cancer using PD-1 axis binding antagonists and taxanes
WO2016207717A1 (en)2015-06-242016-12-29Janssen Pharmaceutica NvAnti-vista antibodies and fragments
EP3325010B1 (en)2015-07-232023-06-21The Regents of The University of CaliforniaAntibodies to coagulation factor xia and uses thereof
CN108135958B (en)2015-08-062022-03-04希望之城Cell penetrating protein-antibody conjugates and methods of use thereof
EP4223784A3 (en)2015-09-022023-10-04The Regents of the University of Colorado, a body corporateCompositions and methods for modulating t-cell mediated immune response
WO2017062682A2 (en)2015-10-062017-04-13Genentech, Inc.Method for treating multiple sclerosis
CA2946113A1 (en)2015-10-232017-04-23Pfizer Inc.Anti-il-2 antibodies and compositions and uses thereof
CA3007997A1 (en)2015-12-102017-06-15City Of HopeCell penetrating cyanine-coupled antibodies
MX391382B (en)2015-12-242025-03-21Corvus Pharmaceuticals Inc CANCER TREATMENT METHODS
CN108430455A (en)2015-12-302018-08-21豪夫迈·罗氏有限公司 Use of tryptophan derivatives for protein formulations
SG11201804961UA (en)2015-12-302018-07-30Genentech IncFormulations with reduced degradation of polysorbate
BR112018011029A2 (en)2016-01-082018-11-21Hoffmann La Roche methods for treating or delaying cancer progression and improving immune function in a cancer individual, uses of a binding antagonist and a bispecific antibody, compositions and kits
DK3405490T3 (en)2016-01-212022-01-10Pfizer MONO- AND BISPECIFIC ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III AND CD3 AND USES THEREOF
CN109073635A (en)2016-01-252018-12-21豪夫迈·罗氏有限公司Method for measuring T cell dependence bispecific antibody
CA3019952A1 (en)2016-02-042017-08-10Curis, Inc.Mutant smoothened and methods of using the same
MX2018009800A (en)2016-02-122018-11-09Janssen Pharmaceutica NvAnti-vista (b7h5) antibodies.
JP7034489B2 (en)2016-03-152022-03-14アイタブメッド (エイチケイ) リミテッド Multispecific Fab fusion protein and its use
EA201892190A1 (en)2016-03-292019-04-30Янссен Байотек, Инк. TREATMENT OF PSORIASIS WITH ANTI-BODY TO IL-12 AND / OR IL-23 WITH THE GROWTH OF THE INTERVAL BETWEEN THE INTRODUCTION OF DOSE
CA3019130A1 (en)2016-04-012017-10-05The Regents Of The University Of CaliforniaInhibitors of integrin alpha 5 beta 1 and methods of use
WO2017175058A1 (en)2016-04-072017-10-12Janssen Pharmaceutica NvAnti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP3455364A2 (en)2016-05-102019-03-20H. Hoffnabb-La Roche AgMethods of decreasing trisulfide bonds during recombinant production of polypeptides
WO2017218977A2 (en)2016-06-172017-12-21Genentech, Inc.Purification of multispecific antibodies
AU2017300788B2 (en)2016-07-222023-11-16Dana-Farber Cancer Institute, Inc.Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
CN106079858B (en)*2016-08-032017-05-17钟晴晴Silk screen printer
US11046776B2 (en)2016-08-052021-06-29Genentech, Inc.Multivalent and multiepitopic antibodies having agonistic activity and methods of use
CN109476748B (en)2016-08-082023-05-23豪夫迈·罗氏有限公司 Methods for the treatment and diagnosis of cancer
HRP20250718T1 (en)2016-08-152025-08-15F. Hoffmann-La Roche Ag CHROMATOGRAPHIC METHOD FOR QUANTIFICATION OF NON-IONIC SURFACTANT IN A COMPOSITION CONTAINING NON-IONIC SURFACTANT AND POLYPEPTIDE
WO2018045379A1 (en)2016-09-022018-03-08Dana-Farber Cancer Institute, Inc.Composition and methods of treating b cell disorders
US20190233505A1 (en)2016-09-062019-08-01Dana-Farber Cancer Institute, Inc.Methods of treating or preventing zika virus infection
TW201825674A (en)2016-09-092018-07-16美商艾斯合顧問有限公司Oncolytic virus expressing bispecific engager molecules
JP7072576B2 (en)2016-09-162022-05-20シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド Anti-PD-1 antibody
PE20191148A1 (en)2016-09-232019-09-02Teva Pharmaceuticals Int Gmbh TREATMENT OF REFRACTORY MIGRANA
WO2018055573A1 (en)2016-09-232018-03-29Teva Pharmaceuticals International GmbhTreating cluster headache
EP3515494A4 (en)2016-09-262020-10-07The Brigham and Women's Hospital, Inc. B-CELL-MEDIATED IMMUNSUPPRESSION REGULATORS
CA3036232A1 (en)2016-09-292018-04-05The Regents Of The University Of CaliforniaNeutralizing antibodies to the .alpha.v.beta.8 integrin complex for immunotherapy
KR20190059305A (en)2016-09-302019-05-30얀센 바이오테크 인코포레이티드 A safe and effective way to treat psoriasis with anti-IL23-specific antibodies
CA3040812A1 (en)2016-11-042018-05-11Novimmune SaAnti-cd19 antibodies and methods of use thereof
US11008325B2 (en)2016-11-142021-05-18Virginia Commonwealth UniversityInhibitors of cancer invasion, attachment, and/or metastasis
WO2018093841A1 (en)2016-11-162018-05-24Janssen Biotech, Inc.Method of treating psoriasis with anti-il-23 specific antibody
WO2018129029A1 (en)2017-01-042018-07-12Immunogen, Inc.Met antibodies and immunoconjugates and uses thereof
EP3565845A4 (en)2017-01-062020-10-07Biosion, Inc. ERBB2 ANTIBODIES AND THEIR USES
WO2018152496A1 (en)2017-02-172018-08-23The Usa, As Represented By The Secretary, Dept. Of Health And Human ServicesCompositions and methods for the diagnosis and treatment of zika virus infection
RU2019127550A (en)2017-03-032021-04-05Ринат Ньюросайенс Корп. ANTI-GITR ANTIBODIES AND METHODS OF THEIR USE
US11726091B2 (en)2017-04-032023-08-15The Regents Of The University Of CaliforniaCompositions and methods of diagnosing pancreatic cancer
US20230192839A1 (en)2017-04-122023-06-22Pfizer Inc.Antibodies having conditional affinity and methods of use thereof
RU2665790C1 (en)2017-04-172018-09-04Закрытое Акционерное Общество "Биокад"Monoclonal pd-l1 antibody
EP4230649A3 (en)2017-04-252023-10-25The U.S.A. As Represented By The Secretary, Department Of Health And Human ServicesAntibodies and methods for the diagnosis and treatment of epstein barr virus infection
JP7295030B2 (en)2017-04-262023-06-20ユーリカ セラピューティックス, インコーポレイテッド Construct that specifically recognizes glypican 3 and use thereof
JOP20190256A1 (en)2017-05-122019-10-28Icahn School Med Mount SinaiNewcastle disease viruses and uses thereof
EP3630167A1 (en)2017-05-262020-04-08NovImmune SAAnti-cd47 x anti-mesothelin antibodies and methods of use thereof
TWI757499B (en)2017-06-022022-03-11美商輝瑞大藥廠Antibodies specific for flt3 and their uses
US11827669B2 (en)2017-07-192023-11-28The Usa, As Represented By The Secretary, Dept. Of Health And Human ServicesAntibodies and methods for the diagnosis and treatment of hepatitis b virus infection
US20200354452A1 (en)2017-09-292020-11-12City Of HopeCars and bispecific antibodies for treatment of mantle cell lymphoma
RU2698048C2 (en)2017-10-032019-08-21Закрытое Акционерное Общество "Биокад"Monoclonal antibody to il-5rα
MA50580A (en)2017-11-062020-09-16Janssen Biotech Inc SAFE AND EFFECTIVE METHOD OF TREATING PSORIASIC ARTHRITIS WITH A SPECIFIC ANTIBODY ANTI-IL23
EP3746482A1 (en)2018-02-012020-12-09Pfizer Inc.Antibodies specific for cd70 and their uses
MX2020009265A (en)2018-03-052020-10-01Janssen Biotech IncMethods of treating crohn's disease with anti-il23 specific antibody.
WO2019178248A1 (en)2018-03-132019-09-19The Regents Of The University Of CaliforniaInhibitors of integrin alpha 2 beta 1 and methods of use
WO2019175658A1 (en)2018-03-142019-09-19Novimmune SaAnti-cd3 epsilon antibodies and methods of use thereof
CN108357203A (en)*2018-04-232018-08-03广州市威顿彩印有限公司A kind of color printing producing line rotary blade type drying equipment and its application method
US12084489B2 (en)2018-05-022024-09-10The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesAntibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection
EP3790587A4 (en)2018-05-112022-01-26Janssen Biotech, Inc. METHOD OF TREATMENT OF DEPRESSION USING IL-23 ANTIBODIES
CA3100829A1 (en)2018-05-232019-11-28Pfizer Inc.Antibodies specific for gucy2c and uses thereof
WO2019224385A2 (en)2018-05-242019-11-28Glenmark Pharmaceuticals S.A.Combined bispecific antibody and immuno-oncology therapies
EP3810777A4 (en)2018-06-212022-03-30Yumanity Therapeutics, Inc.Compositions and methods for the treatment and prevention of neurological disorders
SG11202012446UA (en)2018-06-232021-01-28Genentech IncMethods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
AU2019295855A1 (en)2018-06-292021-01-28City Of HopeCD6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
WO2020014306A1 (en)2018-07-102020-01-16Immunogen, Inc.Met antibodies and immunoconjugates and uses thereof
AU2019305637A1 (en)2018-07-182021-03-11Genentech, Inc.Methods of treating lung cancer with a PD-1 axis binding antagonist, an antimetabolite, and a platinum agent
US20200025776A1 (en)2018-07-182020-01-23Janssen Biotech, Inc.Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
MX2021001453A (en)2018-08-082021-04-12Genentech IncUse of tryptophan derivatives and l-methionine for protein formulation.
WO2020041758A1 (en)2018-08-242020-02-27City Of HopeMasked cytokine conjugates
JP2022501388A (en)2018-09-192022-01-06ラホヤ インスティチュート フォー イミュノロジー PTPRS and proteoglycans in rheumatoid arthritis
CA3111809A1 (en)2018-09-212020-03-26Genentech, Inc.Diagnostic methods for triple-negative breast cancer
EP3877407A1 (en)2018-11-052021-09-15F. Hoffmann-La Roche AGMethods of producing two chain proteins in prokaryotic host cells
AU2019383017A1 (en)2018-11-202021-06-03Janssen Biotech, Inc.Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
AU2020257748A1 (en)2019-04-192021-11-18Chugai Seiyaku Kabushiki KaishaChimeric receptor recognizing modification site of antibody
CN113874073A (en)2019-05-232021-12-31詹森生物科技公司Methods of treating inflammatory bowel disease with combination therapy of antibodies to IL-23 and TNF α
CA3142580A1 (en)2019-06-032020-12-10Janssen Biotech, Inc.Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
TWI870412B (en)2019-06-052025-01-21美商建南德克公司A method for regeneration of an overload chromatography column
CN114341187A (en)2019-07-122022-04-12中外制药株式会社Anti-mutant FGFR3 antibodies and uses thereof
EP4004037A1 (en)2019-07-262022-06-01Vanderbilt UniversityHuman monoclonal antibodies to enterovirus d68
US12098212B2 (en)2019-08-122024-09-24Purinomia Biotech, Inc.Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
WO2021028752A1 (en)2019-08-152021-02-18Janssen Biotech, Inc.Anti-tfn antibodies for treating type i diabetes
EP4084808A1 (en)2019-12-302022-11-09City of HopeMethods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
EP4103602A1 (en)2020-02-112022-12-21Vanderbilt UniversityHuman monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)
SMT202400070T1 (en)2020-03-262024-03-13Univ VanderbiltHuman monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021195385A1 (en)2020-03-262021-09-30Vanderbilt UniversityHUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
WO2021205325A1 (en)2020-04-082021-10-14Pfizer Inc.Anti-gucy2c antibodies and uses thereof
MX2021015024A (en)2020-04-282022-01-18Univ RockefellerNeutralizing anti-sars-cov-2 antibodies and methods of use thereof.
US20210347880A1 (en)2020-05-052021-11-11Janssen Biotech, Inc.Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
AU2021276930A1 (en)2020-05-212023-02-02Janssen Biotech, Inc.Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
MX2022015877A (en)2020-06-162023-01-24Genentech IncMethods and compositions for treating triple-negative breast cancer.
WO2022013745A1 (en)2020-07-132022-01-20Janssen Biotech, Inc.Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
IL299939A (en)2020-07-172023-03-01PfizerTherapeutic antibodies and their uses
AR123997A1 (en)2020-11-042023-02-01Univ Rockefeller NEUTRALIZING ANTIBODIES AGAINST SARS-CoV-2
WO2022155324A1 (en)2021-01-152022-07-21The Rockefeller UniversityNeutralizing anti-sars-cov-2 antibodies
JP2024503724A (en)2021-01-202024-01-26オンコレスポンス,インク. Immunomodulatory antibodies and their uses
MX2023010705A (en)2021-03-122023-11-22Janssen Biotech IncSafe and effective method of treating psoriatic arthritis with anti-il23 specific antibody.
JP2024510588A (en)2021-03-122024-03-08ヤンセン バイオテツク,インコーポレーテツド Method of treating psoriatic arthritis patients with inadequate response to TNF therapy with anti-IL23-specific antibodies
US20220315654A1 (en)2021-03-222022-10-06Novimmune SaBispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
US20220315655A1 (en)2021-03-222022-10-06Novimmune SaBispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
EP4334343A2 (en)2021-05-062024-03-13The Rockefeller UniversityNeutralizing anti-sars- cov-2 antibodies and methods of use thereof
JP2024541946A (en)2021-10-292024-11-13ヤンセン バイオテツク,インコーポレーテツド Methods of treating Crohn's disease with anti-IL23 specific antibodies
EP4426730A1 (en)2021-11-052024-09-11Dana-Farber Cancer Institute, Inc.Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
EP4433501A1 (en)2021-11-152024-09-25Janssen Biotech, Inc.Methods of treating crohn's disease with anti-il23 specific antibody
EP4436997A1 (en)2021-11-232024-10-02Janssen Biotech, Inc.Method of treating ulcerative colitis with anti-il23 specific antibody
EP4469159A1 (en)2022-01-272024-12-04The Rockefeller UniversityBroadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
CN114485122A (en)*2022-02-242022-05-13广西青松木业有限公司Tunnel type timber veneer drying production line
WO2023178357A1 (en)2022-03-182023-09-21Evolveimmune Therapeutics, Inc.Bispecific antibody fusion molecules and methods of use thereof
CN119698430A (en)2022-03-302025-03-25詹森生物科技公司 Methods for treating mild to moderate psoriasis with IL-23 specific antibodies
KR20240165358A (en)2022-04-012024-11-22제넨테크, 인크. Hydroxypropyl methyl cellulose derivatives for stabilizing polypeptides
GB202204813D0 (en)2022-04-012022-05-18Bradcode LtdHuman monoclonal antibodies and methods of use thereof
US20250289903A1 (en)2022-04-292025-09-18Purinnomia Biotech, Inc.Methods and compositions for treating eosinophil driven diseases and disorders
WO2023215498A2 (en)2022-05-052023-11-09Modernatx, Inc.Compositions and methods for cd28 antagonism
US20230374122A1 (en)2022-05-182023-11-23Janssen Biotech, Inc.Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
AU2023362569A1 (en)2022-10-212025-04-24Novimmune SaPd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
WO2024097639A1 (en)2022-10-312024-05-10Modernatx, Inc.Hsa-binding antibodies and binding proteins and uses thereof
CN120569403A (en)2022-11-222025-08-29詹森生物科技公司 Method for treating ulcerative colitis with anti-IL23 specific antibodies
WO2024118866A1 (en)2022-12-012024-06-06Modernatx, Inc.Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024173607A2 (en)2023-02-142024-08-22Evolveimmune Therapeutics, Inc.Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
WO2024206126A1 (en)2023-03-272024-10-03Modernatx, Inc.Cd16-binding antibodies and uses thereof
WO2025059037A1 (en)2023-09-112025-03-20Evolveimmune Therapeutics, Inc.Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
CN117190671B (en)*2023-09-132025-08-26莱阳银通纸业有限公司 A seed paper rapid air drying device and method
WO2025064885A1 (en)2023-09-202025-03-27Evolveimmune Therapeutics, Inc.Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
WO2025064890A1 (en)2023-09-202025-03-27Evolveimmune Therapeutics, Inc.Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
WO2025072888A2 (en)2023-09-282025-04-03Novavax, Inc.Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
WO2025114357A1 (en)2023-11-282025-06-05Novimmune SaMethod of treating disease using anti-cd47 x anti-mesothelin antibodies as a sole agent and in combination with anti-pd-1 antibodies
WO2025196691A1 (en)2024-03-202025-09-25Janssen Biotech, Inc.Methods of treating crohn's disease with anti-il23 specific antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US1543585A (en)*1923-03-241925-06-23Heekin Can CompanySynchronized press and oven conveyer
GB793216A (en)*1956-02-181958-04-09James Arthur BlackImprovements in or relating to a method of and machine or apparatus for drying coated sheet stock
DE1222083B (en)*1962-04-021966-08-04Rank Xerox Ltd Device for transporting paper or the like sheets

Also Published As

Publication numberPublication date
DE2860970D1 (en)1981-11-12
EP0003089A1 (en)1979-07-25
FR2413974B1 (en)1982-12-03
EP0003089B1 (en)1981-08-12

Similar Documents

PublicationPublication DateTitle
FR2413974A1 (en) DRYER FOR SCREEN-PRINTED SHEETS
CH611954A5 (en)Apparatus for recovering heat energy from waste water and for saving water, especially in laundries
IT8405243A0 (en) TRIGGER MECHANISM FOR THE TRANSFORMATION OF AUTOMATIC RIFLES WITH CLOSED BOLT INTO RIFLES WITH OPEN BOLT.
FR2508993A1 (en) DOUBLE SERIES DISPLACEMENT LYOPHILIZATION SYSTEM
NL7707121A (en) DESIGN AND METHOD FOR PRACTICALLY KEEPING THE EFFICIENCY IN DIFFERENT OPERATING REGIMES OF APPLIANCES WITH COMBUSTION SYSTEM WITH FORCED DRAIN.
NL7712326A (en) DEVICE FOR SAVING ENERGY IN MILK INSTALLATIONS.
DK0452844T3 (en) Process for freezing food products in containers and an automatic plate freezer for carrying out the process
US3712285A (en)Metal foil reflector holder for cooking grills
GB867591A (en)Broiler
DK166064B (en) Oven for drying and welding of pig carcasses
ES2044721T3 (en) HOLDING FRAME FOR A CONTINUOUS TRANSPORT DEVICE.
US3087416A (en)Charcoal grill
SU1646952A1 (en)Work-piece tranportation plant
FR2671167B1 (en) METHOD AND DEVICE FOR FIREPLACES WITH OPEN FIRE INDEPENDENTLY FROM THE AIR IN THE ROOM.
JPS6014789Y2 (en) Fabric transfer processing equipment
US3665539A (en)Automatic shackle washer
KR910019571A (en) Automatic cooking equipment
JPS5371342A (en)Heating cooking device
SU631823A1 (en)Freezing chamber
SU525608A1 (en) Gripping device
GR890100434A (en)Small litter basket
FR2546578B1 (en) CLAMP WITH NUT AND WASHER CLOSURE ATTACHED BETWEEN THEM
JPH0488942A (en)Sun-drying equipment for fish and shellfish
JPS5448369A (en)Direct heating system clothes dryer
JPS56138025A (en)Charging hole opening and closing device for powder and granule transport

Legal Events

DateCodeTitleDescription
TPTransmission of property
CLConcession to grant licences
STNotification of lapse

[8]ページ先頭

©2009-2025 Movatter.jp